|
|
Blood, 15 November 2005, Vol. 106, No. 10, pp. 3594-3601.
Prepublished online as a Blood First Edition Paper on August 4, 2005; DOI 10.1182/blood-2005-02-0487.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
A redox signature score identifies diffuse large B-cell lymphoma patients with a poor prognosis
Margaret E. Tome,
David B. F. Johnson,
Lisa M. Rimsza,
Robin A. Roberts,
Thomas M. Grogan,
Thomas P. Miller,
Larry W. Oberley, and
Margaret M. Briehl
From the Departments of Pathology and Hematology Oncology, University of Arizona, Tucson; and the Department of Radiation Research, University of Iowa, Iowa City.
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease in which approximately 40% of the patients respond well to current chemotherapy, but the prognosis for the other 60% is poor. The Leukemia/Lymphoma Molecular Profiling Project (LLMPP) used microarray technology to define a molecular profile for each of 240 patients with DLBCL and develop a molecular outcome predictor score that accurately predicted patient survival. Data from our laboratory and others suggest that alterations in antioxidant defense enzyme levels and redox environment can be oncogenic and affect the response to glucocorticoid treatment, one of the components of combination chemotherapy regimens for lymphoma. The goal of the current study was to reanalyze the LLMPP microarray data to determine whether the levels of antioxidant defense enzymes and redox proteins were correlated with prognosis in DLBCL. We found that patients with DLBCL with the worst prognosis, according to the outcome predictor score, had decreased expression of catalase, glutathione peroxidase, manganese superoxide dismutase, and VDUP1, a protein that inhibits thioredoxin activity. The data suggest that the patients with the worst prognosis combine a decrease in antioxidant defense enzyme expression with an increase in thioredoxin system function (the redox signature score).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. C. Jaramillo, J. B. Frye, J. D. Crapo, M. M. Briehl, and M. E. Tome
Increased Manganese Superoxide Dismutase Expression or Treatment with Manganese Porphyrin Potentiates Dexamethasone-Induced Apoptosis in Lymphoma Cells
Cancer Res.,
July 1, 2009;
69(13):
5450 - 5457.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. M. Rimsza, M. L. LeBlanc, J. M. Unger, T. P. Miller, T. M. Grogan, D. O. Persky, R. R. Martel, C. M. Sabalos, B. Seligmann, R. M. Braziel, et al.
Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP
Blood,
October 15, 2008;
112(8):
3425 - 3433.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A Mukherjee and S G Martin
The thioredoxin system: a key target in tumour and endothelial cells
Br. J. Radiol.,
October 1, 2008;
81(Special_Issue_1):
S57 - S68.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Turturro, G. Von Burton, and E. Friday
Hyperglycemia-Induced Thioredoxin-Interacting Protein Expression Differs in Breast Cancer-Derived Cells and Regulates Paclitaxel IC50
Clin. Cancer Res.,
June 15, 2007;
13(12):
3724 - 3730.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Andreadis, P. A. Gimotty, P. Wahl, R. Hammond, J. Houldsworth, S. J. Schuster, and T. R. Rebbeck
Members of the glutathione and ABC-transporter families are associated with clinical outcome in patients with diffuse large B-cell lymphoma
Blood,
April 15, 2007;
109(8):
3409 - 3416.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Reue and L. Vergnes
Thematic review series: Systems Biology Approaches to Metabolic and Cardiovascular Disorders. Approaches to lipid metabolism gene identification and characterization in the postgenomic era
J. Lipid Res.,
September 1, 2006;
47(9):
1891 - 1907.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
